These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 31648447)

  • 21. Association of plasma levels of soluble receptor for advanced glycation end products and risk of kidney disease: the Atherosclerosis Risk in Communities study.
    Rebholz CM; Astor BC; Grams ME; Halushka MK; Lazo M; Hoogeveen RC; Ballantyne CM; Coresh J; Selvin E
    Nephrol Dial Transplant; 2015 Jan; 30(1):77-83. PubMed ID: 25147225
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advanced glycation end products, leukocyte telomere length, and mitochondrial DNA copy number in patients with coronary artery disease and alterations of glucose homeostasis: From the GENOCOR study.
    Vecoli C; Basta G; Borghini A; Gaggini M; Del Turco S; Mercuri A; Gastaldelli A; Andreassi MG
    Nutr Metab Cardiovasc Dis; 2022 May; 32(5):1236-1244. PubMed ID: 35260310
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationships between vitreous levels of soluble receptor for advanced glycation end products (sRAGE) and renal function in patients with diabetic retinopathy.
    Katagiri M; Shoji J; Kato S; Kitano S; Uchigata Y
    Int Ophthalmol; 2017 Dec; 37(6):1247-1255. PubMed ID: 27830398
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target.
    Geroldi D; Falcone C; Emanuele E
    Curr Med Chem; 2006; 13(17):1971-8. PubMed ID: 16842191
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Possible Impact of Hyperuricemia on Serum Soluble Receptor for Advanced Glycation end Products (sRAGE) Levels in Teenagers: A Case Control Study.
    Lemiesz M; Tenderenda-Banasiuk E; Sosnowska D; Rybi-Szumińska A; Storonowicz J; Lemiesz T; Wasilewska A
    Curr Pharm Des; 2018; 24(27):3232-3239. PubMed ID: 30101695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum levels of advanced glycation end-products (AGEs) and the decoy soluble receptor for AGEs (sRAGE) can identify non-alcoholic fatty liver disease in age-, sex- and BMI-matched normo-glycemic adults.
    Palma-Duran SA; Kontogianni MD; Vlassopoulos A; Zhao S; Margariti A; Georgoulis M; Papatheodoridis G; Combet E
    Metabolism; 2018 Jun; 83():120-127. PubMed ID: 29409822
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between circulating soluble receptor for advanced glycation end products and atherosclerosis: observations from the Dallas Heart Study.
    Lindsey JB; de Lemos JA; Cipollone F; Ayers CR; Rohatgi A; Morrow DA; Khera A; McGuire DK
    Diabetes Care; 2009 Jul; 32(7):1218-20. PubMed ID: 19366975
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Critical Appraisal of Advanced Glycation End Products (AGEs) and Circulating Soluble Receptors for Advanced Glycation End Products (sRAGE) as a Predictive Biomarkers for Cardiovascular Disease in Hemodialysis Patients.
    Assiri AMA; Kamel HFM; ALrefai AA
    Med Sci (Basel); 2018 May; 6(2):. PubMed ID: 29789493
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association between Advanced Glycation End Products, Soluble RAGE Receptor, and Endothelium Dysfunction, Evaluated by Circulating Endothelial Cells and Endothelial Progenitor Cells in Patients with Mild and Resistant Hypertension.
    Gryszczyńska B; Budzyń M; Begier-Krasińska B; Osińska A; Boruczkowski M; Kaczmarek M; Bukowska A; Iskra M; Kasprzak MP
    Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31412635
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes.
    Nakamura K; Yamagishi S; Adachi H; Kurita-Nakamura Y; Matsui T; Yoshida T; Imaizumi T
    Mol Med; 2007; 13(3-4):185-9. PubMed ID: 17592553
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Relationship between the Soluble Receptor for Advanced Glycation End Products and Oxidative Stress in Patients with Palmoplantar Warts.
    Mitran CI; Nicolae I; Tampa M; Mitran MI; Caruntu C; Sarbu MI; Ene CD; Matei C; Ionescu AC; Georgescu SR; Popa MI
    Medicina (Kaunas); 2019 Oct; 55(10):. PubMed ID: 31635193
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Correlation of the expressions of advanced glycation end products and its receptor in serum and placenta with the pathogenesis of preeclampsia].
    Xian N; Chen W; Zhang Y; Li J; Zhang N; Ye Y
    Zhonghua Fu Chan Ke Za Zhi; 2015 Jul; 50(7):493-9. PubMed ID: 26311638
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hemodialysis Patients with Higher Serum Levels of Soluble Receptor for Advanced Glycation End Products Have an Increased Risk for Arteriovenous Fistula Failure.
    Ticala M; Rusu CC; Moldovan D; Potra AR; Tirinescu DC; Coman AL; Bondor CI; Budisan L; Kacsó IM
    Blood Purif; 2022; 51(9):764-771. PubMed ID: 34794141
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An investigation of the relationship between rheumatological diseases and soluble receptor for advanced glycation end products.
    Okuyucu M; Kehribar DY; Çelik ZB; Özgen M
    Eur Rev Med Pharmacol Sci; 2022 May; 26(10):3450-3455. PubMed ID: 35647825
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fluorescent advanced glycation end products and their soluble receptor: the birth of new plasmatic biomarkers for risk stratification of acute coronary syndrome.
    Raposeiras-Roubín S; Rodiño-Janeiro BK; Paradela-Dobarro B; Grigorian-Shamagian L; García-Acuña JM; Aguiar-Souto P; Jacquet-Hervet M; Reino-Maceiras MV; González-Juanatey JR; Álvarez E
    PLoS One; 2013; 8(9):e74302. PubMed ID: 24058542
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low plasma levels of the soluble receptor for advanced glycation end products in HIV-infected patients with subclinical carotid atherosclerosis receiving combined antiretroviral therapy.
    Jeong SJ; Kim CO; Song YG; Baek JH; Kim SB; Jin SJ; Ku NS; Han SH; Choi JY; Lee HC; Kim JM
    Atherosclerosis; 2011 Dec; 219(2):778-83. PubMed ID: 21872861
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma levels of soluble receptor for advanced glycation end products and coronary atherosclerosis: possible correlation with clinical presentation.
    Falcone C; Bozzini S; D'Angelo A; Matrone B; Colonna A; Benzi A; Paganini EM; Falcone R; Pelissero G
    Dis Markers; 2013; 35(3):135-40. PubMed ID: 24167358
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association between plasma sRAGE and emphysema according to the genotypes of AGER gene.
    Sin S; Lim MN; Kim J; Bak SH; Kim WJ
    BMC Pulm Med; 2022 Feb; 22(1):58. PubMed ID: 35144588
    [TBL] [Abstract][Full Text] [Related]  

  • 39. AGE-RAGE Stress and Coronary Artery Disease.
    Prasad K
    Int J Angiol; 2021 Mar; 30(1):4-14. PubMed ID: 34025091
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes.
    Yamagishi S; Matsui T; Nakamura K
    Curr Drug Targets; 2007 Oct; 8(10):1138-43. PubMed ID: 17979674
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.